


AD-A187 897 ROLE OF ADENOSINE ANALOGS AND GROWTH HORMONE IN WAKING
AND SLEEP(U) ILLINOIS UNIV AT THE MEDICAL CENTER
CHICAGO COLL OF MEDICINE. M RADULOVACKI 16 OCT 87
UNCLASSIFIED AFOSR-TR-87-1687 AFOSR-85-0349

1/1

F/B 6/15

NL





FILE COPY		REPORT DOCUMENTATION PAGE		AD-A187 897		2	
1a. REPORT SECURITY CLASSIFICATION Unclassified				3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release distribution unlimited			
2a. SECURITY CLASSIFICATION AUTHORITY DTIC ELECTED				5. MONITORING ORGANIZATION REPORT NUMBER(S) AFOSR-TR-87-1687			
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE NOV 30 1987				4. PERFORMING ORGANIZATION REPORT NUMBER(S) GID			
6a. NAME OF PERFORMING ORGANIZATION University of Illinois College of Medicine		6b. OFFICE SYMBOL (If applicable)		7a. NAME OF MONITORING ORGANIZATION Air Force Office of Scientific Research N/L			
6c. ADDRESS (City, State, and ZIP Code) P.O. Box 6998 Chicago, IL 60612		7b. ADDRESS (City, State, and ZIP Code) Building 410 Bolling AFB, DC 20332-6448		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER AFOSR-85-0349			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION AFOSR		8b. OFFICE SYMBOL (If applicable) NL		10. SOURCE OF FUNDING NUMBERS			
8c. ADDRESS (City, State, and ZIP Code) Building 410 Bolling AFB, DC 20332-6448		PROGRAM ELEMENT NO. 61102F		PROJECT NO. 2312		TASK NO. A2	
11. TITLE (Include Security Classification) Role of adenosine analogs and growth hormone in waking and sleep		13b. TIME COVERED FROM 9/15/86 TO 9/15/87		14. DATE OF REPORT (Year, Month, Day) October 16, 1987		15. PAGE COUNT	
12. PERSONAL AUTHOR(S) Miodrag Radulovacki		13a. TYPE OF REPORT Annual		16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)					
FIELD		GROUP		SUB-GROUP			
19. ABSTRACT (Continue on reverse if necessary and identify by block number) The role of adenosine in sleep has been further investigated using electroencephalography to document the dose-response effects of newly developed specific adenosine A ₁ and A ₂ receptor stimulants and 8-cyclopropyltheophylline (CPRT), a substituted xanthine. The results with adenosine agonists suggest that both A ₁ and A ₂ receptors play a role in the hypnotic action of adenosine. The data with CPRT point out that stimulant effect of xanthines is obtained by the blockade of A ₁ receptors. Desensitization of adenosine A ₂ receptors was found following the chronic treatment of adenosine agonists L-PIA, NECA and deoxycoformycin. Chronic administration of caffeine "up-regulates" A ₁ receptors in cerebral cortex in a manner similar to that following deprivation of REM sleep. This suggests the existence of an "endocaffeine" whose normal role is to block adenosine receptors during prolonged sleep deprivation- a mechanism that could be responsible for the increased number of adenosine receptors.							
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS				21. ABSTRACT SECURITY CLASSIFICATION Unclassified			
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. William O. Berry				22b. TELEPHONE (Include Area Code) (202) 767-5021		22c. OFFICE SYMBOL NL	

2. Research Objectives

- A. Our first objective in determining the mechanism of hypnotic action of adenosines was to test the dose-response effects on sleep of newly developed adenosine A_1 and A_2 receptor stimulants, i.e. N^6 -1-methylcyclopentyladenosine (RAO 119-A), N^6 -cyclopentyladenosine (CPA) and 2-(phenyl-amino) adenosine (CV-1808), respectively.
- B. Our second major objective in determining the mechanism of hypnotic effects on sleep of 8-cyclopropyltheophylline (CPRT), a substituted xanthine which preferentially antagonises adenosine 1 receptors. Our objective was to find out whether blockade of A_1 receptors would increase waking, since xanthines block both A_1 and A_2 receptors.
- C. The third important objective in our research was to investigate the effect of chronic administration of adenosine agonists (1-PIA, NECA, dexoycoformycin) and non-specific antagonists (caffeine) on central A_1 and A_2 receptors in rats. It was of interest to establish whether and in which brain structures adenosine receptors can be "down-regulated" or "up-regulated".

3. Status of Research

- A. When newly developed specific adenosine A_1 receptor stimulants became available, we examined the dose response effects on sleep of N^6 -1-methylcyclopentyladenosine (Rao 119-A), a specific A_1 receptor agonist (1). The various doses of the drug administered intraperitoneally to rats affected sleep stages differently and the data are in agreement with previously reported effects on sleep of adenosine receptor stimulants. Of the newly developed adenosine A_1 and A_2 receptor stimulants we tested the dose-response effects on sleep in N^6 -cyclopentyladenosine (CPA), the most potent and selective adenosine A_1 receptor agonist, and 2-(phenylamino) adenosine (CV-1808) the most selective adenosine A_2 receptor agonist. Both drugs were administered intraperitoneally to rats and the results suggest that both adenosine A_1 and A_2 receptors play a role in the hypnotic action of adenosine (2).
- B. In order to accomplish our second major objective we tested the dose-response effects on sleep of 8-cyclopropyltheophylline (CPRT) (3). Although a substituted xanthine, CPRT has been reported to have sedative and hypnotic effects in high doses. However, in reported experiments only gross behavioral measures

of sedation were employed. We found that CPRT produces biphasic and dose-dependent effects on sleep and wakefulness in rats. Thus, 20 and 40 mg/kg doses decreased sleep (an indirect evidence of a selective A₁ receptor blockade) and 80 mg/kg dose (toxic) increased sleep.

In these experiments we have shown that selective blockade of A₁ receptors is able to produce a state of sustained wakefulness. The findings suggest that adenosinergic system, particularly A₁ receptors, play important role in sleep and wakefulness.

C. Our third major objective was accomplished when

- a. Maximally tolerated doses of N⁶-R-PIA (0.50 nmoles/hr/2 weeks) NECA (0.04 nmoles/hr/2 wk) or deoxycoformycin (DCF, 5 nmoles/hr/1 wk) were administered intracerebroventricularly to rats using ALZET mini-osmotic pumps. Adenosine receptor function was subsequently assayed using both ligand binding and adenylate cyclase assays. Binding to A₁ receptors was quantitated using [³H]R-PIA, a selective agonist ligand at A₁ receptors. Differences in the binding of this ligand and that of [³H]NECA, which binds to A₁ and A₂ receptors with similar affinities, were used to quantitate A₂ receptors. None of the treatments affected A₁ receptor function. A₂ receptor binding and A₂ receptor mediated stimulation of adenylate cyclase were blunted in striatal membranes from NECA and DCF treated rats. The results suggest that only A₂ receptors were desensitized following the treatment of adenosine agonists (4).
- b. We administered to rats caffeine (75 mg/kg/day, i.p.) for 12 days and obtained a significant increase in high affinity [³H]R-PIA binding in cerebral cortex (14%, p<0.02). [³H]R-PIA minus [³H]NECA binding for the estimation of A₂ receptors in striatum showed only an upward trend in B_{max}. The results show that chronic treatment with high doses of caffeine can selectively increase A₁ receptor population in cortex, while these doses have no effect on A₂ receptors. (5)

4. Written Publications

1. Radulovacki, M., Hajduk, P., Stefanovich, P. and Porter, N.: The effects of N⁶-1-Methylcyclopentyladenosine on sleep in rats. Res. Comm. Psych. Behav. 12(1) 1-8, 1987.
2. Porter, N.M., Stefanovich, P., Hajduk, P. and Radulovacki, M.: The effects of N⁶-cyclopentyladenosine and 2-(phenylamino) adenosine on sleep in rats. Brain Res. Bull. (submitted).
3. Virus, R.M. and Radulovacki, M.: Dose-response effects of 8-cyclopropyltheophylline on sleep and wakefulness in rats. Psychopharmacology (in press).
4. Porter, N.M., Radulovacki, M. and Green, R.D.: Desensitization of adenosine and dopamine receptors in rat brain following treatment with adenosine analogues. J. Pharmacol. Exp. Ther. (in press).
5. Dugich, M., Hawkins, M., Porter, N.M. and Radulovacki, M.: Effect of chronic caffeine administration on adenosine A₁, adenosine A₂ and benzodiazepine receptors in specific areas of the rat brain. Soc. Neurosci. Abstr. 13: (Part 2) 1346, 1987.

5. Professional Personnel

Marjorie Hawkins, M.D.
Robert M. Virus, Ph.D.
Nada Porter, Graduate Student
Millicent Dugich, Graduate Student
Phillip Hajduk, Undergraduate Student
Alex Radetich, Undergraduate Student
Peter Stefanovich, Medical Student

6. Interactions

Hawkins, M., M. Pravica, and M. Radulovacki: Effects of chronic administration of diazepam and RO-15-1788 on adenosine A₁ and A₂ receptors in the rat brain. Soc. Neurosci. Meeting, Nov. 9-14, 1986, Washington, D.C.

Glaum, S.R., G. Yanik, W. Pan, P. Hajduk and M. Radulovacki: Low doses of caffeine affect sleep composition in a manner opposite to that of adenosine analogs in rats. Soc. Neurosci. Meeting, Nov. 9-14, 1986, Washington, D.C.

Porter, N.M., F.M. Clark, R.D. Green and M. Radulovacki: Down-regulation of adenosine A₂ receptors is associated with an increase in deep slow wave sleep. Soc. Neurosci. Meeting, Nov. 9-14, Washington, D.C.

Radulovacki, M.: Adenosine compounds and sleep. International Symposium "Current Trends in Slow Wave Sleep Research", June 25-27, 1987, Beerse, Belgium. (a co-organizer)

Radulovacki, M.: Central adenosine receptors and sleep. Symposium on "Receptor Mechanisms in Sleep" 5th International Congress of Sleep Research, June 28-July 3, 1987, Copenhagen, Denmark, (invited speaker)



Accession No.	
NTIS GRA&I	✓
DTIC TAB	
Unannounced	
Justification	
By	
Date	
A-1	

END

DATE

FILMED

FEB.

1988